Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic and therapeutic impact of argininosuccinate synthetase 1 control in bladder cancer as monitored longitudinally by PET imaging.
Allen MD, Luong P, Hudson C, Leyton J, Delage B, Ghazaly E, Cutts R, Yuan M, Syed N, Lo Nigro C, Lattanzio L, Chmielewska-Kassassir M, Tomlinson I, Roylance R, Whitaker HC, Warren AY, Neal D, Frezza C, Beltran L, Jones LJ, Chelala C, Wu BW, Bomalaski JS, Jackson RC, Lu YJ, Crook T, Lemoine NR, Mather S, Foster J, Sosabowski J, Avril N, Li CF, Szlosarek PW. Allen MD, et al. Among authors: ghazaly e. Cancer Res. 2014 Feb 1;74(3):896-907. doi: 10.1158/0008-5472.CAN-13-1702. Epub 2013 Nov 27. Cancer Res. 2014. PMID: 24285724
Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo.
Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, Liapis K, Grantham M, Sohrabi F, Cavenagh J, Bomalaski JS, Gribben JG, Szlosarek PW, Bonnet D, Taussig DC. Miraki-Moud F, et al. Among authors: ghazaly e. Blood. 2015 Jun 25;125(26):4060-8. doi: 10.1182/blood-2014-10-608133. Epub 2015 Apr 20. Blood. 2015. PMID: 25896651 Free article.
A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW. Phillips MM, et al. Among authors: ghazaly e. Pharmacol Rep. 2023 Jun;75(3):570-584. doi: 10.1007/s43440-023-00480-6. Epub 2023 Apr 3. Pharmacol Rep. 2023. PMID: 37010783 Free PMC article.
Correction: A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma.
Phillips MM, Pavlyk I, Allen M, Ghazaly E, Cutts R, Carpentier J, Berry JS, Nattress C, Feng S, Hallden G, Chelala C, Bomalaski J, Steele J, Sheaff M, Balkwill F, Szlosarek PW. Phillips MM, et al. Among authors: ghazaly e. Pharmacol Rep. 2023 Jun;75(3):753. doi: 10.1007/s43440-023-00487-z. Pharmacol Rep. 2023. PMID: 37195562 Free PMC article. No abstract available.
Anti-tumour activity of a first-in-class agent NUC-1031 in patients with advanced cancer: results of a phase I study.
Blagden SP, Rizzuto I, Suppiah P, O'Shea D, Patel M, Spiers L, Sukumaran A, Bharwani N, Rockall A, Gabra H, El-Bahrawy M, Wasan H, Leonard R, Habib N, Ghazaly E. Blagden SP, et al. Among authors: ghazaly e. Br J Cancer. 2018 Oct;119(7):815-822. doi: 10.1038/s41416-018-0244-1. Epub 2018 Sep 12. Br J Cancer. 2018. PMID: 30206366 Free PMC article. Clinical Trial.
28 results